
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July, 2019

Commission File Number: 001-38452

MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

**4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Mereo BioPharma Group plc
Holding(s) in Company

London, July 8, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today provided a regulatory news service (RNS) notification of major holdings through the London Stock Exchange plc, a copy of which is provided below.

RNS Number : 8439E
Mereo BioPharma Group plc
08 July 2019

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible) ⁱ				
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:	Mereo Biopharma Group PLC			
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)				
Non-UK issuer	<input type="checkbox"/>			
2. Reason for the notification (please mark the appropriate box or boxes with an "X")				
An acquisition or disposal of voting rights	<input type="checkbox"/>			
An acquisition or disposal of financial instruments	<input type="checkbox"/>			
An event changing the breakdown of voting rights	<input type="checkbox"/>			
Other (please specify) ⁱⁱⁱ : No trading in the stock - voting control interest over stock transferred to new manager	<input checked="" type="checkbox"/>			
3. Details of person subject to the notification obligation^{iv}				
Name	Woodford Investment Management Ltd			
City and country of registered office (if applicable)	9400 Garsington Road, Oxford, OX4 2HN, United Kingdom			
4. Full name of shareholder(s) (if different from 3.) ^v				
Name				
City and country of registered office (if applicable)				
5. Date on which the threshold was crossed or reached^{vi}:	05/07/2019			
6. Date on which issuer notified (DD/MM/YYYY):	08/07/2019			
7. Total positions of person(s) subject to the notification obligation				
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^{vii}

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")			
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{xiii}			X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{xiv} (please add additional rows as necessary)			
Name ^{xv}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Woodford Investment Management Ltd	27.56	0.00	27.56

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information^{xvi}

Place of completion	9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
Date of completion	08/07/2019

Further Enquiries**Mereo**

Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer

+44 (0)333 023 7300**Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo)**

Phil Davies
Will Goode

+44 (0)20 7894 7000**RBC Capital Markets (Joint Broker to Mereo)**

Rupert Walford
Jamil Miah

+44 (0)20 7653 4000**FTI Consulting (Public Relations Adviser to Mereo)**

Simon Conway
Brett Pollard
Ciara Martin

+44 (0)20 3727 1000**Burns McClellan (US Public Relations Adviser to Mereo)**

Lisa Burns
Steve Klass

+01 (0)212 213 0006

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 8, 2019

MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel